Viatris (VTRS) | Stock Overview & Key Data
Viatris Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $76.69 on April 20, 2015
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Dividend Information
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Viatris
VTRS
|
16.99B Large-cap | 2.45% | -0.97% | 20.80% | 39.97% | 30.98% | 84.75% | 60.16% | 15.57% | -63.39% | -26.00% | -21.07% |
|
Zoetis
ZTS
|
49.75B Large-cap | 0.16% | 3.42% | -31.08% | -32.94% | -36.81% | -51.58% | -53.40% | -57.08% | 71.34% | 156.59% | 156.59% |
|
Haleon Plc - ADR
HLN
|
42.40B Large-cap | 2.02% | 1.23% | -13.29% | -7.73% | -9.30% | -16.01% | 8.43% | 23.21% | 23.21% | 23.21% | 23.21% |
|
United Therapeutics
UTHR
|
25.11B Large-cap | 0.90% | -3.34% | 2.86% | 9.85% | 10.64% | 92.68% | 137.11% | 205.88% | 434.68% | 903.79% | 2,026.01% |
|
Intra-Cellular
ITCI
|
14.05B Large-cap | N/A | N/A | N/A | N/A | N/A | 92.68% | 104.13% | 700.67% | 449.92% | 632.61% | 632.61% |
| 14.00B Large-cap | -20.10% | -40.20% | -24.65% | -0.98% | -16.80% | 20.24% | 2,888.89% | 6,625.00% | 6,625.00% | 6,625.00% | 6,625.00% |
Ownership & Short Interest
Calculate Your Viatris Investment Returns
Long-Term Investment Performance Analysis
Viatris stock price in Jul 2016 was $46.59, A $1,000.00 lump sum investment in Viatris made 9 years ago would be worth approximately $350.29 today, representing a negative return of -64.97%. This translates to an annualized return (CAGR) of -10.05%.
9 Years 10 Months Investment Scenario (Jul 2016 - Jun 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is VTRS's 52-week high and low?
- In the last 52 weeks, Viatris reached a high of $17.53 (on May 14, 2026) and a low of $8.63 (on August 1, 2025).
- What is the market cap and P/E ratio for VTRS?
- Curious about Viatris's size and valuation? Its market capitalization stands at 16.99B. When it comes to valuation, the P/E ratio (trailing twelve months) is 235.80, and the forward P/E (looking ahead) is 5.54.
- Does VTRS pay dividends? If so, what's the yield?
- Yes, Viatris is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 4.02%, and the company has paid an average of $0.52 per share annually over the past 3 years.
- Who are Viatris's main competitors or similar companies to consider before investing?
When looking at Viatris, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Zoetis
ZTS49.75B Healthcare Drug Manufacturers - Specialty & Generic -51.58% -53.40% Haleon Plc - ADR
HLN42.40B Healthcare Drug Manufacturers - Specialty & Generic -16.01% 8.43% United Therapeutics
UTHR25.11B Healthcare Drug Manufacturers - Specialty & Generic 92.68% 137.11% Intra-Cellular
ITCI14.05B Healthcare Drug Manufacturers - Specialty & Generic 92.68% 104.13% Regencell Bioscience
RGC14.00B Healthcare Drug Manufacturers - Specialty & Generic 20.24% 2,888.89% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Viatris Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Viatris's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -21.08%, the Debt to Equity ratio from the most recent quarter is 99.91, and its Gross Profit Margin stands at 30.99%.
- What is the recent revenue and earnings growth for VTRS?
- Looking at Viatris's growth, its revenue over the trailing twelve months (TTM) was $14B. Compared to the same quarter last year (YoY), quarterly revenue grew by 5.00%, and quarterly earnings saw a YoY growth of 4.97%.
- How much of VTRS stock is held by insiders and institutions?
- Wondering who owns Viatris stock? Company insiders (like executives and directors) hold about 0.45% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 86.66%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.